HLHua Li

Hua Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hua Li has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Shuguang Zhu

    Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

    6 shared publications
  • Haoqi Chen

    Department of Hepatic Surgery, Liver Transplantation The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China

    5 shared publications
  • Yang Yang

    Department of Hepatic Surgery & Liver Transplantation The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

    4 shared publications
  • Changchang Jia

    Department of Cell-Gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

    3 shared publications
  • Wenfeng Zhu

    Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    3 shared publications
  • Xiaolong Chen

    Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Multi-omics reveals the DR5-FXR-CHPT1 axis governs hepatocyte pyroptosis via glycerophospholipid remodeling after major partial hepatectomy in male mice

    by Yongsheng Tang, Xu Lu, Xi Luo, Qinghai Lian, Yingqiu Song, Manqiu Kang, Zihan Qiao, Zhihua Rao, Linsen Ye, Zenan Yuan, et al.

    Severe liver injury following major partial hepatectomy (PHx) carries high mortality, yet the mechanisms driving irreversible cell death remain poorly understood. Here we show that aberrant lipid metabolism drives inflammatory cell death in the remaining liver tissue. Integrating data from male mouse models and human tissues, we found that death receptor 5 (DR5) acts as a critical regulator. Mechanistically, DR5 impedes the nuclear entry of the Farnesoid X Receptor (FXR), repressing the production of phosphatidylcholine (PC), an essential structural lipid. This lipid deficiency compromises the integrity of cellular membranes, causing severe stress and lethal pyroptosis. Restoring this pathway via DR5 suppression, FXR activation, or PC supplementation significantly alleviated post-surgical liver injury. Overall, we uncover a non-canonical metabolic function of DR5 that disrupts cellular homeostasis. These findings suggest that modulating this metabolic pathway may offer potential avenues for investigating future management strategies for small-for-size syndrome (SFSS) and post-hepatectomy liver failure (PHLF).

  • Open Access

    Intervening in PIDD1 to Decrease Treg Cell Recruitment Boosts the Effectiveness of Radiofrequency Ablation Combined with anti-PD-1 Therapy in HCC

    by Xu Lu, Zhiyong Xiong, Yongsheng Tang, Yingqiu Song, Zenan Yuan, Ling Li, Manqiu Kang, Xin He, Zihan Qiao, Shuguang Zhu, et al.

  • Open Access

    A multi‐centre, prospective trial of a methylation‐based liquid biopsy for early detection of liver cancer in high‐risk populations

    by Ruohan Zhang, Xinrong Yang, Guangming Li, Yinan Deng, Jibing Liu, Hongjun Gao, Jie Zhao, Jianwen Cheng, Xiaofei Zhao, Yang Yang, et al.

    Background and aims: Existing imaging and serum‐marker assays miss many early liver cancers, especially in high‐risk chronic liver disease carriers. We aimed to create a highly accurate, non‐invasive, methylation‐based liquid biopsy for early detection. Methods: We used a comprehensive, multi‐platform, multi‐cohort strategy for marker discovery, starting with methylation profiling of hepatocellular carcinoma samples from TCGA and in‐house cohorts. From 30 initial candidates, nine highly liver‐specific methylation markers were shortlisted, and three optimal cfDNA markers (RNF135, CHFR, PAX5) were selected to develop a robust diagnostic model, tuned in a training set ( N = 280) and locked in an internal testing set ( N = 124). The model was then validated in a prospective, large‐scale trial conducted at four geographically distinct Chinese centres. Results: The clinical trial included 1097 participants from two groups, (i) a diagnosing group ( N = 646) that prospectively enrolled individuals without prior diagnostic results and represented a real‐world high‐risk population, and (ii) a diagnosed group recruited after pathology confirmation. Overall, the model achieved 94.43% (95% confidence interval, 92.12–96.09%) sensitivity and 95.16% (92.78–96.78%) specificity for liver cancer, with stage‐I sensitivity of 93.10% (89.78–95.40%). Within the diagnosing group, overall sensitivity was 93.99% (91.28–95.90%), and for the 267 stage‐I cases, it reached 92.88% (89.15–95.39%). As for specificity, it remained high across confounders: 92.78% (85.84–96.46%) in cirrhosis, 91.74% (85.46–95.45%) in other‐cancer interference samples. Besides, the model outperformed the traditional liver cancer biomarker AFP and showed changes in methylation signals before and after surgery, suggesting a possible role in perioperative monitoring. Each centre independently reported sensitivities and specificities exceeding 90%, demonstrating robust geographic performance. Conclusions: Using a systematic marker‐discovery pipeline and a multi‐centre prospective cohort, we developed a methylation‐based liquid biopsy that reliably detects early liver cancer in high‐risk populations. Clinical trial number: Chictr.org identifier: ChiCTR2400092883. Key points: Three cfDNA methylation markers, RNF135, CHFR and PAX5, were identified for liver cancer liquid biopsy. A three‐marker diagnostic model based on qMSP was established for highly accurate non‐invasive detection of liver cancer. The LC‐HMC model achieved 94.43% sensitivity and 95.16% specificity in the clinical trial. The model detected stage‐I liver cancer with a sensitivity of 93.10%.


  • Open Access

    Prompt-mamba filtering networks for accurate hepatocellular carcinoma lesion segmentation in abdominal CT

    by Long Xia, Hai-Yang Chen, Ya-Wen Cao, Chen-Quan Gan, Jun-Zhang Zhao, Wei-Hua Zheng, Haiwen Jia, Shuai Jiang, Xuwang Li, Hua Li, et al.

    Precise delineation of hepatocellular carcinoma (HCC) in abdominal CT is pivotal for early diagnosis and surgical planning, yet remains challenged by morphological heterogeneity, low contrast in small lesions, and scanner variability. To address these limitations, we propose Prompt-Mamba-AF, a framework tailored for robust HCC segmentation. Our method uniquely integrates anatomy-aware prompts to guide feature extraction within liver regions and leverages Mamba-based state-space modeling to capture long-range volumetric dependencies with linear complexity. Furthermore, we introduce structure-aware filtering to enforce topological consistency along lesion boundaries. Extensive validation on the LiTS, 3DIRCADb, and CHAOS benchmarks demonstrates that Prompt-Mamba-AF outperforms current state-of-the-art CNN and Transformer architectures. The model achieves leading Dice similarity and boundary accuracy while maintaining a compact parameter footprint (27.6M). Results indicate significant improvements in small nodule sensitivity and generalization across diverse imaging domains, positioning Prompt-Mamba-AF as an efficient solution for multi-center clinical workflows.

  • Open Access

    Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

    by Yutao Chen, Desheng Chen, Zhixing Liang, Haoyuan Yu, Haobin Sun, Yongwei Hu, Peng Jiang, Mingshen Zhang, Linsen Ye, Hua Li

    Hepatocellular carcinoma (HCC) poses a significant clinical burden due to its aggressive nature, profound tumor heterogeneity, and limited therapeutic efficacy. While immune checkpoint inhibitors (ICIs) have revolutionized treatment paradigms and demonstrated considerable promise, the emergence of resistance mechanisms has posed a critical challenge in contemporary clinical oncology. The accelerated development of novel agents and innovative combination strategies has further complicated this resistance landscape. In this review, we present a unique and comprehensive analysis of ICI resistance mechanisms in HCC by integrating insights into primary resistance, acquired resistance, and host-related factors. Building upon this mechanistic framework, we explore emerging therapeutic strategies to overcome ICI resistance. Furthermore, we evaluate the dual role of ICIs in HCC management - serving as a neoadjuvant therapy for transplant candidates while simultaneously posing risks of post-transplant rejection. By bridging preclinical discoveries with clinical realities, this analysis aims to inform rational therapeutic design and optimize immuno-oncology trials for HCC patients.


  • Open Access

    KYNA Ameliorates Hepatic Ischemia–Reperfusion Injury by Activating the Hippo Signalling Pathway via FTO‐Dependent m6A Demethylation of LATS1

    by Wenjie Zheng, Xiaowen Wang, Haoqi Chen, Kaiming He, Xijing Yan, Yuan Zhang, Yang Yang, Peng Zhang, Wenfeng Zhu, Shuguang Zhu, et al.

    Hepatic ischemia–reperfusion injury (HIRI) substantially influences the prognosis of liver transplant recipients. Although kynurenic acid (KYNA) has been associated with protective effects against ischemia–reperfusion injury in various organs, the precise mechanisms underlying its protective role in HIRI are not well elucidated. In this study, a 70% mouse HIRI model and an in vitro hypoxia/reoxygenation model were employed to examine the protective effects of KYNA on HIRI. In this study, we illustrate that KYNA influences the methylation status of the Hippo signalling pathway by enhancing the expression of the fat mass and obesity‐associated gene (FTO). Within this pathway, large tumour suppressor kinase 1 (LATS1) is identified as a direct target of FTO. Moreover, the stability of LATS1 mRNA exhibits an inverse correlation with FTO levels and is modulated through its interaction with YTH N6‐Methyladenosine RNA Binding Protein F2 (YTHDF2). The reduction in LATS1 expression facilitated Yes‐associated protein (YAP) nuclear translocation, decreased hepatocyte apoptosis, and mitigated HIRI. Clinically, elevated levels of serum KYNA correlate with a diminished severity of liver injury post‐transplantation. our work revealed that KYNA possesses significant clinical translational potential for the prevention of HIRI, and further exploration of its underlying mechanisms was conducted.


  • Open Access

    Integrative cross‐tissue analysis unveils complement‐immunoglobulin augmentation and dysbiosis‐related fatty acid metabolic remodeling during mammalian aging

    by Feng Zhang, Rong Li, Yasong Liu, Jinliang Liang, Yihang Gong, Cuicui Xiao, Jianye Cai, Tingting Wang, Qiang You, Jiebin Zhang, et al.

    Aging‐related decline and adaptation are complex, multifaceted processes that affect various tissues and increase risk of chronic diseases. To characterize key changes in cross‐tissue aging, we performed comprehensive proteomic and metabolomic analyses across 21 solid tissues and plasma samples, alongside shotgun metagenomic profiling of fecal microbial communities in young and aged mice. Our findings revealed widespread aging‐rewired chronic inflammation, characterized by complement system activation in plasma and universal immunoglobulins accumulation across multiple solid tissues. This inflammatory remodeling significantly enhanced vulnerability to aging‐related tissue injury. Moreover, we identified organ‐specific and organ‐enriched proteins with high functional specificity. Among these, aging‐related proteins were closely linked to disorders arising from lipid metabolism dysfunction. Analysis of multi‐tissue metabolomic and fecal metagenomic profiles revealed that aging significantly disrupted inter‐tissue metabolic coupling, activities of polyunsaturated fatty acids metabolism, and gut microbiota homeostasis. Aged mice exhibited a marked decrease in Escherichia and an increase in Helicobacter, strongly correlating with alterations in omega‐3 and omega‐6 fatty acid abundances. Through multi‐omics integration, we identified key molecular hubs driving organismal responses to aging. Collectively, our study uncovers extensive aging‐associated alterations across tissues, emphasizing the interplay between systemic inflammation and dysbiosis‐driven fatty acid remodeling. These findings provide deeper insights into the development of healthy aging from a cross‐tissue perspective.


  • Open Access

    Development and clinical validation of a novel platelet count-based nomogram for predicting microvascular invasion in HCC

    by Wenjie Zheng, Haoqi Chen, Jianfeng Zhang, Kaiming He, Wenfeng Zhu, Xiaolong Chen, Xijing Yan, Zexin Lin, Yang Yang, Xiaowen Wang, et al.

    We aimed to develop a convenient nomogram to predict preoperative MVI in patients with hepatocellular carcinoma (HCC). Patients who underwent surgical resection due to HCC from June 2018 to June 2023 at the Third Affiliated Hospital of Sun Yat-sen University were retrospectively reviewed. Univariate and multivariable logistic linear regression analyses were used to investigate potential risk factors for MVI. A nomogram was plotted based on these risk factors. The tumor diameter (≥ 5 cm), BCLC stage, PLT (>127.50 × 109/L), AST (>29.50 U/L) and AFP (>10.07 ng/ml) were identified as independent preoperative risk factors for MVI by univariate and multivariable logistic analysis. The nomogram demonstrated decent accuracy in estimating the presence of MVI, with an AUC of 0.69 (95%CI: 0.64–0.73). The calibration curves exhibited a close match between the predicted probabilities and the actual estimates of MVI in the nomogram (p = 0.947). Decision curve analysis (DCA) revealed that the prediction model had a high net benefit if the threshold probability>20%. High platelet counts were strongly associated with the presence of MVI in HCC patients. Our convenient nomogram demonstrated decent accuracy in estimating the presence of MVI and had notable clinical application.


  • Open Access

    Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study

    by Wenfeng Zhu, Weilong Wang, Wenjie Zheng, Xiaolong Chen, Xiaowen Wang, Juping Xie, Shijie Jiang, Haoqi Chen, Shuguang Zhu, Ping Xue, et al.

    Protein induced by vitamin K absence or antagonist II (PIVKA-II) plays a critical role in the diagnosis of hepatocellular carcinoma (HCC), however, studies on its efficacy in diagnosing recurrent HCC were rarely found. A multicenter, retrospective, and observational study was conducted. During the overall follow-up of 5 years, HCC patients who had curative resection were monitored every 3 months in the first year post-surgery and every 6 months thereafter if no recurrence occurred. Tumor markers were collected at the diagnosis of recurrence for those with recurrence and at the last follow-up for those without recurrence. The median serum levels of PIVKA-II and AFP in the recurrence group were significantly higher than those in the non-recurrence group (PIVKA-II: 84.62 vs. 18.76 mAU/ml, p < 0.001; AFP: 4.90 vs. 3.00 ng/ml, p < 0.001) and there is a significant correlation between PIVKA-II and AFP (R = 0.901, p < 0.001). PIVKA-II showed better accuracy than AFP in the diagnosis of overall recurrent HCC (AUC: 0.883 vs. 0.672; p < 0.0001), but also in patients with negative PIVKA-II before curative resection (AUC: 0.878 vs. 0.680, p = 0.001). Clinician should pay more attention to serum PIVKA-II values when following patients after curative HCC resection to detect early recurrence.Clinical trial registration: ChiCTR2300070874


  • Open Access

    RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway

    by Yongsheng Tang, Zenan Yuan, Xu Lu, Yingqiu Song, Shuguang Zhu, Chunhui Qiu, Qi Zhang, Binsheng Fu, Changchang Jia, Hua Li

    Hepatic ischemia-reperfusion injury (HIRI) is a prevalent complication of liver transplantation, partial hepatectomy, and severe infection, necessitating the development of more effective clinical strategies. Receptor activity–modifying protein 1 (RAMP1), a member of the G protein–coupled receptor adapter family, has been implicated in numerous physiological and pathological processes. The study aimed to investigate the pathogenesis of RAMP1 in HIRI.